GHRH receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
特沙莫瑞林的检测通常依赖反相高效液相色谱和质谱联用。反相色谱可分离肽主峰与缺失序列、氧化产物等杂质，质谱则提供精确质量以确认身份。对于复杂基质中的定量，常采用液相色谱-串联质谱，并配合固相萃取或蛋白沉淀。生物样品中的肽易降解，因此采集和处理条件会影响结果。
稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定，复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集，这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。
=== Historic and laboratory routes === Fumaric acid was first prepared from succinic acid. A traditional synthesis involves oxidation of furfural (from the processing of maize) using chlorate in the presence of a vanadium-based catalyst.
=== Commemorations === Oregon State University completed construction of the $77 million, 100,000-square-foot (9,300 m2) Linus Pauling Science Center in the late 2000s, now housing the bulk of Oregon State's chemistry classrooms, labs, and instruments. On March 6, 2008, the United States Postal Service released a 41 cent stamp honoring Pauling designed by artist Victor Stabin. His description reads: "A remarkably versatile scientist, structural chemist Linus Pauling (1901–1994) won the 1954 Nobel Prize in Chemistry for determining the nature of the chemical bond linking atoms into molecules. His work in establishing the field of molecular biology; his studies of hemoglobin led to the classification of sickle cell anemia as a molecular disease." The other scientists on this sheet of stamps included Gerty Cori, biochemist, Edwin Hubble, astronomer, and John Bardeen, physicist. California Governor Arnold Schwarzenegger and First Lady Maria Shriver announced on May 28, 2008, that Pauling would be inducted into the California Hall of Fame, located at The California Museum for History, Women and the Arts. The induction ceremony took place December 15, 2008. Pauling's son Linus Jr. was asked to accept the honor in his place. By proclamation of Gov. John Kitzhaber in the state of Oregon, February 28 has been named "Linus Pauling Day". The Linus Pauling Institute still exists, but moved in 1996 from Palo Alto, California, to Corvallis, Oregon, where it is part of the Linus Pauling Science Center at Oregon State University.
On May 12, 2026, Montreal-based franchisor Foodtastic agreed with American company Inspire Brands, owner of Dunkin', to open hundreds of Canadian locations in late 2026 or early 2027 after an absence of eight years in Canada.
Sources: en.wikipedia.org
=== Anraj Chabra === Anraj Chabra (Irfan Shamji) is a mild-mannered junior trader at Pierpoint working under Rishi, who frequently takes his anger out on him. Rishi uses Anraj's account to run a £300 million long on pound sterling against the US dollar, raising major flags at Pierpoint's risk management division (and jeopardizing Anraj's job and FCA license) until Rishi miraculously nets £18 million from the investment due to a last-minute tax cut by the UK government. Rishi also steals some of Anraj's money (claiming he is using it to bet on horse races) to gamble away at a casino. Anraj later admits that he is afraid to come to work because of Rishi's volatile behavior. Anraj and Sweetpea become friends over the course of their time at Pierpoint, in part due to their mutual frustration with Rishi. Anraj is briefly seen in series 4 attending the ALPHA conference, where Harper publicizes her findings on the fraudulent profits of fintech company Tender; he and Eric exchange a friendly glance.
=== Materials === Over time a wide variety of materials have been used for infant feeding vessels (see History). The materials now most commonly used in baby bottle containers are glass and some types of plastics. Food-grade stainless steel and silicone rubber are also used. Each of these four materials—plastic, glass, silicone and stainless steel—has advantages and disadvantages. The standard materials used in teats/nipples are latex rubber and silicone. A number of countries have regulations about allowable food contact materials. Ideally, the material making up the bottle should react as little as possible with the material in the bottle. No material is completely inert, but glass and stainless steel are relatively neutral materials which tend to remain stable and not interact with foods. The disadvantages of glass are that it tends to be heavy and can break more easily. Plastics are lightweight and resistant to breaking. Manufacturers find them easy to form into a variety of shapes. A wide variety of plastics have been developed, some of which are not well understood in terms of reactivity. Some plastics have been found to be reactive with fluids such as breast milk and infant formula. Chemicals such as Bisphenol A (BPA) may "leach" from a bottle into the substance it holds. In addition, plastics may be more likely to break down when heated or cooled, for example, when being heated in a microwave or being boiled to sterilize them. Polycarbonate plastic was frequently used in baby bottles before 2011, and is still used in some countries.
Baseball Digest All-Star Rookie Team (1998) Associated Press MLB All-Star Team (2000) Baseball Digest MLB Player of the Year (2000) USA Baseball Alumni Player of the Year (2000) Achievements National League (NL) Batting Champion (2000) NL slugging percentage leader (2000) NL RBI leader (2000) NL Doubles leader (2000, Helton hit 59 doubles during the season, which tied Chuck Klein for the third-highest single-season doubles total in NL history.) Hit for the cycle (June 19, 1999) Percentage triple crown (2000) NL hits leader (2000) NL on-base percentage leader (2000, 2005, 2007) NL total bases leader (2000) NL extra base hits leader (2000) Colorado Rockies career leader in games played (2,247), at bats (7,962), runs (1,401), hits (2,519), total bases (4,292), doubles (592), home runs (369), RBI (1,406), walks (1,335), and intentional walks (185). Colorado Rockies retired Helton's number 17 on August 17, 2014. Helton first appeared on the National Baseball Hall of Fame ballot in 2019, when he received 16.5% of the vote, well short of the 75% required for election, but above the 5% minimum required to remain on the ballot. On January 23, 2024, Helton was elected to the Hall of Fame, receiving 79.7% of the vote. He is the second Rockies player, after Larry Walker, to be elected. Helton was formally inducted on July 21, 2024.
Sources: en.wikipedia.org
GC–MS of amphetamine and methamphetamine with the chiral derivatizing agent Mosher's acid chloride allows for the detection of both dextroamphetamine and dextromethamphetamine in urine. Hence, the latter method may be used on samples that test positive using other methods to help distinguish between the various sources of the drug.
And uMRM to facility MRM generation after removal of isotopes and in-source fragments, all without the us of authentic standards. Siuzdak’s recent work has focused on the impact of in-source fragmentation (ISF) and other source-derived processes in mass spectrometry, demonstrating that many signals detected in LC–MS experiments can originate from ion-source–generated artifacts rather than distinct endogenous molecules. Related studies, including work by Richard Zare and colleagues on electrospray-driven chemical transformations (“in-source chemistry”), have further highlighted the potential contribution of ion-source processes to the large number of molecular features commonly observed in untargeted mass spectrometry experiments.
=== Pharmacokinetics === Loratadine when given orally, is well absorbed from the gastrointestinal tract, and has rapid first-pass hepatic metabolism; it is metabolized by isoenzymes of the cytochrome P450 system, including CYP3A4, CYP2D6, and, to a lesser extent, several others. Loratadine is almost totally (97–99%) bound to plasma proteins. Its metabolite desloratadine, which is largely responsible for the antihistaminergic effects, binds to plasma proteins by 73–76%. Loratadine's peak effect occurs after 1–2 hours, and its biological half life is on average eight hours (range 3 to 20 hours) with desloratadine's half-life being 27 hours (range 9 to 92 hours), accounting for its long-lasting effect. About 40% is excreted as conjugated metabolites into the urine, and a similar amount is excreted into the feces. Traces of unmetabolised loratadine can be found in the urine. In structure, it is closely related to tricyclic antidepressants, such as imipramine, and is distantly related to the atypical antipsychotic quetiapine.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.